MedTrace Logo

A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults

NCT05903118 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2024-01-10

No results posted yet for this study

Summary

The phase I/II study is to evaluate the safety and immunogenicity of SARS-COV-2 mRNA Vaccine (RBMRNA-176) at different doses in healthy subjects aged 18 years and older.

Conditions

Interventions

BIOLOGICAL

RBMRNA-176

Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection

OTHER

Placebo

0.9% sodium chloride (normal saline) injection

Sponsors & Collaborators

  • Argorna Pharmaceuticals Co., LTD

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-08
Primary Completion
2022-09-01
Completion
2023-07-19

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05903118 on ClinicalTrials.gov